In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.

ABSTRACT:

Purpose

Combining tumor antigens with an immunostimulant can induce the immune system to specifically eliminate cancer cells. Generally, this combination is accomplished in an ex vivo, customized manner. In a preclinical lymphoma model, intratumoral injection of a Toll-like receptor 9 (TLR9) agonist induced systemic antitumor immunity and cured large, disseminated tumors.

Patients and methods

We treated 15 patients with low-grade B-cell lymphoma using low-dose radiotherapy to a single tumor site and-at that same site-injected the C-G enriched, synthetic oligodeoxynucleotide (also referred to as CpG) TLR9 agonist PF-3512676. Clinical responses were assessed at distant, untreated tumor sites. Immune responses were evaluated by measuring T-cell activation after in vitro restimu

SUBMITTER: Brody JD 

PROVIDER: S-EPMC2954133 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature